FDA advisers say regulators should wait to approve China-developed lung cancer drug

A panel advising U.S. drug regulators said Eli Lilly and Co. and its Chinese partner should conduct more studies of a proposed new lung-cancer drug before approval, citing concerns about the medicine’s testing in China.